GB2580881A — Use of cannabinoids in the treatment of epilepsy
Assigned to GW Research Ltd · Expires 2020-08-05 · 6y expired
What this patent protects
The invention relates to the use of cannabidiol (CBD) in the treatment of epilepsy which results from mutation of the GRIN2A gene. The CBD used may be a purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w). In particular the can…
USPTO Abstract
The invention relates to the use of cannabidiol (CBD) in the treatment of epilepsy which results from mutation of the GRIN2A gene. The CBD used may be a purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w). In particular the cannabinoid tetrahydrocannabinol (THC) is present in an amount of from 0.02 to 0.1% (w/w). Alternatively the CBD may be in a synthetic form. The CBD may be used as a monotherapy or concomitantly with one or more other anti-epileptic drugs (AED). The CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. Where the CBD formulation may be provided as a kit or together with instructions for administration. The epilepsy may be treatment resistant epilepsy (TRE).
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.